← Leaderboards
Kayode K Ojo
University Of Washington
$5,773,228
Attributed
$6,531,053
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,531,053 · 6
By mechanism
R01$4,337,415 · 2
R21$1,428,103 · 3
R56$765,535 · 1
Top collaborators
- Erkang Fan2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Erkang Fan$6,366,172
- Frederick Simmons Buckner$14,937,505
- Alexander Richard Paredez$5,038,624
- Gwendolyn Wood$1,931,162
- Wilhelmus G. J. Hol$41,011,333
Others in their field
Other Emerging Leaders on “Oral”
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Susan Abushakra · Alzheon, Inc.$50,765,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,061,627
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Gary Fanger · Rise Therapeutics, Llc$23,676,385
- James Dale Berry · Brigham And Women'S Hospital$15,344,018
Research focus
OralIn VivoIn VitroInfectionPharmaceutical PreparationsParasitesToxic EffectDrug KineticsResistancePharmaceutical ChemistryPublic HealthMammalian CellIntestinesMetronidazoleMouse ModelCellsDiarrheaGiardiasisChildGrowthEffective TherapyGiardiaGiardia LambliaLibraries
Grant awards (13)
Development of dual effective kinase inhibitors as syndromic treatment of Giardiasis and Cryptosporidiosis$746,285
R01 · FY2025 · AI · contact PI
Discovery of fungus-derived natural products as new and effective Antigiardial agents.$200,086
R21 · FY2025 · AI · contact PI
Methionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeutics$788,438
R01 · FY2024 · AI · contact PI
Development of dual effective kinase inhibitors as syndromic treatment of Giardiasis and Cryptosporidiosis$769,365
R01 · FY2024 · AI · contact PI
Discovery of fungus-derived natural products as new and effective Antigiardial agents.$260,648
R21 · FY2024 · AI · contact PI
Methionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeutics$782,880
R01 · FY2023 · AI · contact PI
Methionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeutics$783,027
R01 · FY2022 · AI · contact PI
Methionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeutics$467,420
R01 · FY2021 · AI · contact PI
Development of Cell-active Giardia lamblia Methionyl-tRNA Synthetase Inhibitors as a New Therapeutic for Giardiasis$765,535
R56 · FY2020 · AI · contact PI
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and Giardiasis$257,125
R21 · FY2020 · AI · contact PI
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and Giardiasis$220,365
R21 · FY2019 · AI · contact PI
Coformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strains$213,389
R21 · FY2018 · AI · contact PI
Coformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strains$276,490
R21 · FY2017 · AI · contact PI